RYTM vs UTHR
Rhythm Pharmaceuticals, Inc. vs United Therapeutics — AI-powered side-by-side comparison
RYTM
Rhythm Pharmaceuticals, Inc.
62
Buy
VS
UTHR
United Therapeutics
72
Buy
| Metric | RYTM | UTHR |
|---|
| AI Score |
62
|
72
|
| Price |
$112.61
|
$514.89
|
| P/E Ratio |
-36.28×
|
17.05×
|
| ROE |
-72.8%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.0%
|
86.1%
|
| Debt / Equity |
0.02×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.9
|
52.2
|
| Beta |
1.974
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for RYTM versus UTHR.
UTHR leads by 10 points.
UTHR scores 72/100 (Buy) versus RYTM at 62/100 (Buy).
RYTM Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 53.5% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 16.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 53.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 26.5x prices in significant intangible value — Value
- ROE of only -80.5% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 16.3% signals elevated volatility — Risk
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.